| content | |||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
O-1125
|
|
| Systematic (IUPAC) name | |
| 6-[(6aR,10aR)-1-hydroxy-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-3-yl]-N,N,6-trimethylheptanamide | |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C26H39NO3 |
| Mol. mass | 413.591 g/mol |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
O-1125 (3-(1,1-dimethylhexyl-6-dimethylcarboxamide)-Δ8-tetrahydrocannabinol) is a drug which is a cannabinoid derivative. It has analgesic effects and is used in scientific research. It is a potent CB1 full agonist with a Ki of 1.16nM.[1]
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
References
- ^ Griffin G, Wray EJ, Martin BR, Abood ME. Cannabinoid agonists and antagonists discriminated by receptor binding in rat cerebellum. British Journal of Pharmacology. 1999 Oct;128(3):684-8. PMID 10516649
